Arvinas to present ARV-102 Phase 1 biomarker data in 2026

Oct 1, 2026 20:01 (23d ago)

Verifying

Arvinas will present biomarker data from the ARV-102 Phase 1 clinical trial.
ARV-102 is described as a PROTAC LRRK2 degrader.
The presentation is scheduled for the 2026 International Congress of Parkinson’s Disease and Movement Disorders®.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.